Indaptus Therapeutics Inc - Asset Resilience Ratio
Indaptus Therapeutics Inc (INDP) has an Asset Resilience Ratio of 33.37% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See INDP working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2010–2023)
This chart shows how Indaptus Therapeutics Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Indaptus Therapeutics Inc (INDP) total assets.
Liquid Assets Composition Over Time
This chart breaks down Indaptus Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read how much debt does Indaptus Therapeutics Inc carry for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $4.00 Million | 33.37% |
| Total Liquid Assets | $4.00 Million | 33.37% |
Asset Resilience Insights
- Very High Liquidity: Indaptus Therapeutics Inc maintains exceptional liquid asset reserves at 33.37% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Indaptus Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Indaptus Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Vaxcyte Inc
NASDAQ:PCVX |
Biotechnology | 41.54% |
|
Bachem Holding AG
SW:BANB |
Biotechnology | 0.00% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 38.51% |
|
Chongqing Zhifei Bio Products
SHE:300122 |
Biotechnology | -0.08% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076 |
Biotechnology | 2.30% |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229 |
Biotechnology | 0.12% |
Annual Asset Resilience Ratio for Indaptus Therapeutics Inc (2010–2023)
The table below shows the annual Asset Resilience Ratio data for Indaptus Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.00% | $0.00 | $14.92 Million | -- |
| 2022-12-31 | 59.88% | $16.81 Million | $28.06 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $40.58 Million | -- |
| 2019-12-31 | 3.62% | $770.00K | $21.28 Million | +1.45pp |
| 2018-12-31 | 2.17% | $1.33 Million | $61.51 Million | -0.66pp |
| 2017-12-31 | 2.83% | $1.82 Million | $64.55 Million | -4.66pp |
| 2016-12-31 | 7.49% | $1.85 Million | $24.72 Million | -11.40pp |
| 2015-12-31 | 18.90% | $7.04 Million | $37.28 Million | +2.81pp |
| 2014-12-31 | 16.08% | $2.01 Million | $12.49 Million | -21.59pp |
| 2013-12-31 | 37.67% | $5.15 Million | $13.68 Million | -1.86pp |
| 2012-12-31 | 39.53% | $3.07 Million | $7.77 Million | +22.72pp |
| 2011-12-31 | 16.81% | $1.52 Million | $9.06 Million | -23.81pp |
| 2010-12-31 | 40.62% | $5.09 Million | $12.54 Million | -- |
About Indaptus Therapeutics Inc
Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and h… Read more